# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Citigroup analyst Carly Kenselaar maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $...
B of A Securities analyst Greg Harrison maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target ...
HC Wainwright & Co. analyst Ed Arce maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target ...
FILSPARI was granted accelerated approval in February 2023 based on the surrogate marker of proteinuria. Full approval is based...